Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy.

Pablo García-PavíaArtur OręziakAhmad Masri Roberto Barriales VillaTheodore P AbrahamAnjali T OwensMorten K JensenWojciech WojakowskiTim SeidlerAlbert A HagègeNeal K LakdawalaAndrew WangMatthew T WheelerLubna ChoudhuryGanesh BalaratnamAshish ShahShawna FoxSheila M HegdeIacopo Olivotto

Published in: European heart journal (2024)

Long-term mavacamten treatment resulted in sustained improvements in cardiac function and symptoms in patients with obstructive HCM, with no new safety concerns identified. Transient, reversible reductions in LVEF were observed in a small proportion of patients during long-term follow-up.

Keyphrases

hypertrophic cardiomyopathy
end stage renal disease
left ventricular
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
heart failure
depressive symptoms
patient reported outcomes
physical activity
combination therapy
patient reported